Edge Therapeutics, a US-based biopharmaceutical company incubated at the New Jersey Institute of Technology, has raised $18m in its series C round. Investment bank Maxim Group was the placement agent and financial adviser for the offering, which will fund a phase II study of its lead product candidate, EG-1962 (nimodipine microparticles), for the prevention of…
Edge cuts into $14m
Jun 12, 2013 •
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Resistance is futile: seven superconductor companies that want to change the world
From healthcare to fusion to quantum computing to space, superconductors have the potential to revolutionise the world. And the technology is finally ready to commercialise.
UK universities urged to lower spinout stakes
A new report recommends stakes of less than 25% but fails to address the issue of access to early-stage capital.
Feb 7, 2024
Mar 14, 2024
Monterey, CA (USA)
Jun 26, 2024